A Phase 2 Study of Durvalumab and Tremelimumab Alone or in Combination With High or Low-Dose Radiation in Metastatic Colorectal and NSCLC

Trial Profile

A Phase 2 Study of Durvalumab and Tremelimumab Alone or in Combination With High or Low-Dose Radiation in Metastatic Colorectal and NSCLC

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
  • Indications Colorectal cancer; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Jun 2017 Planned End Date changed from 7 Jun 2019 to 31 Dec 2020.
    • 14 Jun 2017 Planned primary completion date changed from 7 Jun 2019 to 31 Dec 2020.
    • 14 Jun 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top